DEC 06, 2016 08:00 AM PST
Pre-emptive genotyping for pharmacogenomic risk - establishing a benchmark
SPONSORED BY: Affymetrix
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
6 25 3284

Speakers:
  • Chief - Section of Genomic Pediatrics, and Professor, Department of Pediatrics at the Medical College of Wisconsin
    Biography
      Dr. Broeckel graduated from medical school at the University of Heidelberg, Germany. After residency training in internal medicine and cardiology, he carried out postdoctoral research at the Medical College of Wisconsin (MCW). He joined the faculty at MCW in 2000 and is currently a professor in the Department of Pediatrics and the chief of the Section of Genomic Pediatrics. His research focuses on the identification of genes for complex diseases, understanding gene functions, and the application of genetics and genomics in clinical practice. His work combines clinical applications with functional genome analyses using induced pluripotent stem cells for disease modeling and risk prediction. Dr. Broeckel is the scientific director of a CLIA/CAP-certified clinical laboratory, which conducts clinical testing for structural chromosomal abnormalities as well as pharmacogenetic testing.

    Abstract:
    DATE: December 6, 2016
    TIME: 8:00am PT, 11:00am ET

    Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality in health care. In the US alone, an estimated two million serious ADRs occur annually, causing over 100,000 deaths per year. Based on these estimates, ADRs are the 4th leading cause of death ahead of pulmonary disease, diabetes, AIDS, and pneumonia. The percentage of hospital admissions due to ADRs in some countries exceeds 10%. 

    Due to the magnitude of this problem healthcare organizations and pharmaceutical companies worldwide are developing major initiatives to reduce the cost and impact of ADRs. Pre-emptive pharmacogenomic genotyping is a pivotal new approach using genetic data to gain valuable insights into metabolic status to better understand the cause of adverse events. 

    Ulrich Broeckel, MD and Chief, Section of Genomic Pediatrics at the Medical College of Wisconsin, is a leader in pharmacogenomics research and will share his experience in establishing a new benchmark for pre-emptive genotyping for pharmacogenomics.

    During this session you will learn:
    • How translational clinical researchers gain valuable insight into an individual’s ability to process drugs known to be actionable and where high, moderate, low, preliminary and unknown evidence exists
    • Why genotyping of highly predictive markers in genes including GSTM1, CYP1A2, CYP2D6, CYP2B6, CYP2A6, SULT1A1, CYP2C19, and CYP2C8 that are in highly homologous regions is important 
    • How copy number variation (CNV) analysis for important ADME genes is integrated into the system 
    For Research Use Only. Not for use in diagnostic procedures.

    Show Resources
    Loading Comments...